The clinical utility of gene expression assays in breast cancer patients with 0–3 involved lymph nodes
2021 ◽
Vol 13
◽
pp. 175883592110384
Keyword(s):
Her 2
◽
Multigene expression assays are prognostic for recurrence in hormone-receptor positive 2 (HER-2) negative breast cancer, and, in some cases, predictive of benefit from chemotherapy or extended endocrine therapy. The results of these assays may be used to guide treatment recommendations for early HER-2 negative breast cancer. We review the results of trials establishing the clinical utility of several commercially available gene expression assays.
2021 ◽
2018 ◽
Vol 170
(1)
◽
pp. 69-76
◽
2018 ◽
Vol 36
(15_suppl)
◽
pp. e13000-e13000
Keyword(s):
2019 ◽
Vol 22
(4)
◽
pp. 474-485
◽